Abstract:Objective: The endothelin pathway is implicated in driving pathophysiological changes leading to pulmonary and systemic hypertension, chronic kidney disease and heart failure. Small molecule antagonists that selectively blocked endothelin A receptors (ETA) as well as non-selective ETA and endothelin B receptor (ETB) antagonists were successfully developed for the treatment of these vascular diseases. However, the treatment-related adverse events, such as fluid retention and edema, significantly limit the utility of this class of therapeutics, especially in the heart failure patients. Design and method: A monoclonal antibody that selectively neutralizes endothelin-1 (ET-1) may offer an attractive alternative therapeutic approach that remedies ETA-mediated vasoconstriction without impacting desirable ET-3/ETB mediated fluid regulation. A selective ET-1/2 neutralizing antibody, S69glC21 was discovered and optimized through protein engineering to 80 pM and 30 pM binding affinities to ET-1 and ET-2, respectively. Results: When administered into rats exogenously infused with ET-1, S69glC21 prevented blood pressure increase. In a hypoxia-induced pulmonary hypertension rat model, S69glC21 reduced pulmonary pressure. Compared to atrasentan, a selective small molecule ETA antagonist, S69glC21 had a distinct pharmacodynamic (PD) effect characterized by initial complete inhibition followed by a delayed rise of pulmonary pressure as the hypoxia condition persisted. To further dissect these findings, S69glC21 pharmacokinetics (PK) and circulating ET-1 target engagement (TE) analysis were performed. In the S69glC21 treated rats, antibody bound ET-1 was shown to accumulate relative to baseline plasma levels at all dose levels. In the 30 mpk group, the antibody bound ET-1 accumulated nearly 40,000-fold above the baseline plasma level of 2.25 ± 0.87 pg/mL indicating a rapid production rate of ET-1. Conclusions: Thus, PK/PD modeling reveals significant druggability challenges for the development of a highly effective, commercially viable ET-1 selective neutralizing antibody for the treatment of cardiovascular, pulmonary, and/or renal diseases.

Preparation of Tissue-Specific Monoclonal Antibodies Using Purified Endothelial Membrane Proteins from Biotinylated Pulmonary Vasculature of Rhesus Monkey

A Novel Method to Isolate and Map Endothelial Membrane Proteins from Pulmonary Vasculature

Isolation of Rat Pulmonary Vascular Endothelial Membrane Proteins and Antibody Generation Female

Discovery of a fully human antibody to the proximal membrane terminus of MUC1 based on a B-cell high-throughput screening technique

Preparation and Preliminary Utilization of Monoclonal Antibodies Specifically Against Extracellular Peptide Fragment of Prostate Specific Membrane Antigen

Preparation of anti-recombinant soluble tissue factor monoclonal antibody by trace injecting antigen into spleen

RAPID ENDOGENOUS PRODUCTION OF ENDOTHELIN-1 REVEALED BY AN ENDOTHELIN NEUTRALIZING ANTIBODY IN A SERIES OF EXPERIMENTAL AND MODELING STUDIES

Novel Human/Non-Human Primate Cross-Reactive Anti-Transferrin Receptor Nanobodies for Brain Delivery of Biologics

Monoclonal-antibody-defined human lung tumour cell-surface antigens

Rhesus macaque Bcl-6/Bcl-xL B cell immortalization: Discovery of HIV-1 neutralizing antibodies from lymph node

A SMART method for isolating monoclonal antibodies from individual rhesus macaque memory B cells

Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1

Murine Monoclonal Antibodies Generated Against Mouse/Rat Hemokinin-1

Antigen-Specific Single B Cell Sorting and Monoclonal Antibody Cloning in Guinea Pigs

Preparation and Characterization of the Antibodies Against Human Myofibrillogenesis Regulator 1 and Application in Neonatal Rat Cardiomyocytes

[Preparation and Identification of Monoclonal Antibody Against Repression and Activation Protein 1].

Enzyme-linked immunosorbent assays for quantification of MMAE-Conjugated ADCs and total antibodies in cynomolgus monkey sera

A SMART method for efficiently isolating monoclonal antibodies from individual rhesus macaque memory B cells

Preparation and Characterization of Monoclonal Antibody Against Human LSECtin

[Preparation of functional antibodies targeting tumor endothelia for the treatment of hepatic carcinoma].

Development and Characterization of Monoclonal Antibodies Against Nitro-166Tyrosine of High-Density Lipoprotein: Apolipoprotein A1